Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ERAS-801 |
Synonyms | |
Therapy Description |
ERAS-801 is an EGFR inhibitor with improved blood-brain barrier penetrating ability, potentially leading to inhibition of growth of EGFR-overexpressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ERAS-801 | ERAS801|ERAS 801 | EGFR Inhibitor (Pan) 62 | ERAS-801 is an EGFR inhibitor with improved blood-brain barrier penetrating ability, potentially leading to inhibition of growth of EGFR-overexpressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05222802 | Phase I | ERAS-801 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Active, not recruiting | USA | 0 |